KHIDI is an institution specializing in the planning·evaluation· management of domestic R&D projects related to healthcare.
We invest mainly in promising, next-generation technologies such as innovative new drugs, medical devices, and regenerative medicine and are focusing on supporting the development of medical technologies based on the 4th Industrial Revolution, such as big data and AI. We are also expanding R&D activities into areas to solve social issues such as contagious diseases, dementia, and mental health by reinforcing public investments.

Major Achievements of Healthcare R&D Support

• Development of new drugs

  30 cases

• Development of medical devices

  213 cases

• International
  technology transfer

  79 cases

• Clinical trial

  679 cases

R&D process

Major R&D Projects in Priority Areas

Status of Healthcare R&D Support in the Last 10 Years

Major Achievements

Development of new drugs 30cases

• 16 new drugs, 4 immune vaccines, 6 biopharmaceuticals, 4 natural drugs
  • KANARB (new medication for high blood pressure) :the first drug in Korea to achieve 100 million USD in exports
  • Development of SUPECT: The first Asian drug for treatment of leukemia
  • Development of XCOPRI: A new innovative drug for the treatment of partial-onset seizure epilepsy in adults

• KANARB
• SUPECT
• XCOPRI

Development of medical device (213 cases)

• First in the world to develop L'DISQ Navigable Percutaneous Disc Decompression device for treating herniated disc tissue without surgery (Grade 3 medical device*)

  * There are four grades for medical devices. It is harder to develop and gain permits for higher grade due to higher risk.

• First in the world to develop Hi3-1, multiplex diagnostics for the detection of high-risk group viruses (Grade 4 medical device)
• Development of NOVOSIS, an injection-type bone graft material complex (Grade 4 medical device)

• L’DISQ
• Hi3-1
• NOVOSIS

International pharmaceutical technolocy transfer

* USD 1$ = 1,197.00 KRW (As of July 22, 2020)

• 910 million USD* royalty(equal to 1.10 trillion KRW) for oral targeted anticancer drug between Hanmi Pharmaceutical - Genentech (US) (2016)
• 560 million USD royalty(equal to 670 billion KRW) for cancer immunotherapy between Genexine - I-Mab Biopharma (China) (2017)
• 1.26 billion USD royalty(equal to 1.50 trillion KRW) for lung cancer treatment drug between Yuhan - Janssen (US) (2018)
• 530 million USD royalty(equal to 630 billion KRW) for an anti-epilepotic drug between SK Biopharmaceuticals -Arvelle Therapeutics (Switzerland) (2019)
• 3.84 billion USD royalty(equal to 4,600 billion KRW) for source technology of hypodemic injection between Alteogen – overseas pharmaceutical company (2020)

International Technology Transfer (79 cases)

Journal Publications and Patents

Clinical trials

Number of clinical trials(Year 2018)

• SCI(E) journals

  2,233cases

• Patent application

  993cases

• Patent registration

  616cases

Journal Publications and Patent Achievements (Unit : no. of cases)

Clinical trials

Number of clinical trials (Year 2018)

• Domestic clinical trials

  393 cases

• Multistate clinical trials

  286 cases

• Country ranking for clinical trials
• Seoul City ranking for clinical trials